Media Coverage
LATEST NEWS
LATEST NEWS

Interview with Marton Toth
"We’ve started providing small-scale services for billion dollar companies in this space who are testing our services, The obvious primary target markets are cosmetic and pharmaceutical companies – their current models and operation offer the most seamless integration of our services. All the global pharmaceutical companies are sitting on hundreds of thousands of chemicals in their compound libraries that could be tested for their Longevity effects, but there’s no viable technology for that at the moment.”
Interview with Siva Vinapalli
Katherine White sits down with Siva Vanapalli, a professor of chemical engineering at Texas Tech University and also Co-founder and CEO of Nemalife, a biotech and scientific community dedicated to identifying molecules that promote healthy human life. In this podcast they discuss how the Innovation Hub at Research Park helped launch his company.
June 9, 2022
May 4, 2022
Apr 19, 2022
Apr 19, 2022
DEA registered NemaLife Inc. to work with Schedule 1 substances
NemaLife Inc., completed its DEA schedule 1 registration. If you have scheduled compounds (schedule 1-5) to test reach out to our expert for a free consultation.
March 14, 2022
Canopy Growth Corporation's Vice President of Human & Animal Research,
Dr. Marcel Bonn-Miller is giving a talk about the long-term effects of cannabigerol (CBG) in mice and nematodes at the CannX Medical Cannabis Conference. Similar to CBD, CBG is a phytocannabinoid, with an increasing presence in the worldwide ‘cannabis’ marketplace. Despite the growing pre-clinical literature, no formal toxicity studies had been carried out using CBG
before this study, which includes data from NemaLife's in vivo toxicity platform.
Jan 18, 2022
DEA registered NemaLife Inc. to work with Schedule 2-5 substances
NemaLife Inc., completed its DEA schedule 2-5 registration. If you have scheduled compounds to test reach out to our expert for a free consultation.
July 20, 2021
Nov 20, 2020
Oct 23, 2020
INTERVIEWS
GOVERNMENT GRANTS

Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimer’s Disease (AD/ADRD)
Our multi-prong approach is expected to de-risk drug failure in mammalian AD models. In summary, we will use a novel NemaLife technology to identify a subset of pharmacological longevity interventions will exert neuroprotection against AD-relevant stresses.

New Approaches for Incorporating Genetic Diversity into Toxicity Testing
Our study aims to combine state-of-the art advances in microfluidics, computer vision, laboratory automation and a massively curated genetically diverse nematode species to produce a new screening approach capable of testing thousands of chemicals relevant to agriculture, nutraceutical and biotech markets.